After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.
One biotech portfolio manager thinks Retrophin, the biotech company once run by indicted hedge fund manager Martin Shkreli, could be a promising investment.
The situation in Ireland is improving. Here's a way you can invest in that.
Cramer remains bullish on Cree and thinks Harley-Davidson will continue riding to profit,
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.